Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus Disease 2019 and Dermatology Practice Changes

Angeli Eloise Torres, MD\textsuperscript{a,b,*}, David M. Ozog, MD\textsuperscript{b}, George J. Hruza, MD, MBA\textsuperscript{c}

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has substantially impacted medical practice worldwide. At its peak, lockdown measures were implemented in an effort to curb viral spread and reallocate resources and manpower toward the pandemic response. This situation entailed the closure of ambulatory sites that are deemed nonessential, which included dermatology outpatient clinics. As clinics began to reopen, dermatologists were faced with the challenge of navigating clinical practice while adhering to enhanced safety protocols (ie, physical distancing, mask wearing, frequent hand washing), and teledermatology, often referred to as the "new normal." In this article, we describe how the COVID-19 pandemic has restructured the practice of dermatology and provide a summary of expert guidelines on the safe conduct of dermatology consultations, procedures, and phototherapy in the midst of this global health crisis.

The Rise of Teledermatology

During the height of the COVID-19 pandemic, many workers switched to working remotely to minimize in-person encounters and limit viral transmission. The medical field was no exception, as face-to-face patient encounters have been...
minimized to reduce the need for personal protective equipment (PPE) in short supply, whereas telemedicine was maximized. Telemedicine is defined as “the use of electronic information and communications technologies to provide and support health care when distance separates the participants.” This definition encompasses radio dispatching of emergency personnel, robotic surgery, and telephone and/or video consultations. Being a highly visual field, dermatology is a field well suited to maximize telemedicine. The term “teledermatology” has been used to describe the use of telemedicine to evaluate skin lesions, review laboratory findings, and diagnose and treat patients remotely.

First developed during the 1960s, the practice of teledermatology has increased exponentially in recent years. Teledermatology has proved to be vital during the peak of COVID-19 restrictions and, even as clinics have reopened, teledermatology continued to account for a significant proportion of overall dermatology visits. A recent analysis of trends in teledermatology use found that from May 2020 to June 2020, teledermatology consults for common dermatoses (ie, acne, rosacea, psoriasis, atopic dermatitis, and eczema) increased, whereas consults for skin malignancies decreased. This finding indicates that despite the availability of in-person consultation as an option, both patients and physicians felt comfortable addressing benign skin conditions via teledermatology. It is therefore reasonable to expect the long-term integration of telemedicine into dermatology practice, which necessitates the development of guidelines for optimal delivery of this service (Box 1).

Teledermatology aims to improve access and accessibility to care, increase efficiency, and reduce costs; however, it also has limitations. These limitations include technical difficulties (ie, poor Internet connection), privacy concerns, patient challenges with technology, access to technology, and lack of insurance coverage. In addition, there is potential for misdiagnosis due to incomplete history taking, poor photograph/video quality, and inability to perform physical examination (eg, lesion palpation) and diagnostic procedures. One review reports that more than half of teledermatology consultations require a subsequent in-person visit. Hence, clinicians must assess the appropriateness of teledermatology on a case-to-case basis.

**In-Person Consultation**

Trends in average weekly patient visits during the initial phase of the pandemic (mid-February to mid-April) showed an 81% decline (from 149.7 to 28.2), with an uptick observed in mid-May (96.5 patients seen per week), commensurate with the gradual easing of lockdown restrictions in the United States; this means that from February to May 2020, a potential 10.2 million patient visits were missed, which equates to an estimated decrease in revenue of $2.3 billion. In addition, a global Web-based survey of 733 dermatologists revealed that in-person consultation decreased by 54% following the onset of the pandemic, whereas teledermatology use increased 3-fold. More than two-thirds of survey respondents expect continued use of teledermatology in the future, further emphasizing its role in dermatology practice beyond the pandemic.

Nonetheless, despite its increasing acceptability among both patients and practitioners alike, it is unlikely for teledermatology to entirely replace traditional face-to-face consultation. One study found that when presented with the same patient, there was a high degree of concordance (72%) between the diagnosis made by a dermatologist through teleconsultation and another dermatologist through face-to-face visit. However, it was also noted that 20% of the patients were deemed unfit for teleconsultation. These patients included those with conditions that cannot be sufficiently diagnosed without closer inspection and palpation, dermatoscopy, fungal or viral microscopy, and biopsy. Hence, dermatology practice during the “new normal” involves determining whether a patient is suitable for teledermatology or in-person consultation.

Dermatology practices generally fall under the low-risk category for COVID-19 exposure. However, according to a study by Gerami and Liszewski, a dermatologist is likely to encounter 1 active COVID-19 case per week in the outpatient clinic, given an average of 165 new COVID-19 cases a day in a population of 100,000. Hence, during the pandemic, it is still prudent to have administrative and engineering measures in place to ensure the safety of both patients and staff. The American Academy of Dermatology recommended steps for running dermatology practice during the COVID-19 pandemic, first shared on their Web site in December 2020 (Box 2). Most interim guidelines, when COVID-19 community spread was high, recommended seeing only urgent and essential cases, decreasing opening days and/or hours, reducing the number of staff per shift, and limiting the number of patients seen per day. Intervals in between appointments were lengthened, whereas the actual patient encounter was limited to as little time as possible.
(10–15 minutes). With appointment slots limited, triaging of patients for scheduling of in-person consultation became a necessity. Guidelines for prioritizing limited in-person appointments during the height of the pandemic suggested that precedence should be given to the following\textsuperscript{13}:

- Health care workers with skin diseases that interfere with their delivery of service.
- Patients with severe skin diseases that are potentially life-threatening, functionally debilitating, or cause significant impairment to quality of life.

**Box 1**

**American Telemedicine Association clinical practice guidelines for teledermatology**

| Informed consent and data privacy |
|-----------------------------------|
| - Secure a verbal or written informed consent from the patient before the start of the telemedicine encounter. |

| Physical environment |
|----------------------|
| - Both patient and health care provider should stay in a room or environment that ensures visual and auditory privacy. |
| - Before commencing with the consult, both parties should identify all persons present in the room and verify that all can be clearly seen and heard. |
| - Seating and lighting should be conducive for a professional interaction between the patient and provider. There should be minimal background light from windows or other sources. |
| - Cameras should be placed at eye level on a stable platform to minimize unnecessary movement and allow clear visualization for both parties. |

| Patient evaluation and examination |
|-----------------------------------|
| - The provider should obtain all data necessary to arrive at a diagnosis, differential diagnosis, appropriate workup, and treatment plan. |
| - Although a full-body skin examination is feasible through video consult or photographs, it may not show all skin lesions and surfaces with sufficient detail. Such examination may help to obtain multiple images from several angles and enhance lighting. |
| - For examination of hair-bearing skin, the patient may be required to physically displace or even remove hair. Special lighting may be helpful. |
| - Examination and diagnosis of pigmented lesions may be challenging and require a high index of suspicion. |
| - For examination of mucosal lesions and orifices (including genitalia), special attention should be given to adequate lighting and exposure. |
| - Note that certain lighting and background conditions may alter the color of skin lesions when captured in a photograph or video. |

| Follow-up and care coordination |
|---------------------------------|
| - Coordinate care with the patient’s usual physician (if applicable). |
| - Make referrals as indicated. |
| - Communicate encounter notes to the referring physician and/or the patient. |
| - Formulate a follow-up plan and communicate it to the patient and/or referring physician. |

| Documentation |
|---------------|
| - Document each patient encounter in a secure HIPAA-compliant form and location. |
| - At a minimum, documentation should include a summary of findings, diagnosis and/or differential diagnosis, and management/treatment plan. |
| - Recording of video consults is optional and should be done only with patient consent. |

Data from McKoy K, Antoniotti NM, Armstrong A, et al. Practice Guidelines for Teledermatology. Telemed J E Health. 2016;22(12):981–90.
Box 2
Steps for running dermatology practice during the coronavirus disease 2019 pandemic

Step 1: Be aware of the COVID-19 prevalence in the community.
- Areas with higher prevalence will likely require more stringent infection control measures.

Step 2: Clean and disinfect your practice in accordance with WHO standards.
- Use 70% ethyl alcohol, 0.5% sodium hypochlorite, or any disinfectant product that meets standard criteria for use against SARS-CoV-2.
- In the examination room, clean commonly touched surfaces (eg, tabletop, examination bed/table, door handle/knob, light switch) in between patients.
- Clean all other common areas (eg, bathroom, reception, waiting area) at the end of each day.

Step 3: Reorganize your practice to minimize patient contact and increase sterilization.
- Provide signs and/or floor markings to direct patient traffic and maintain appropriate physical distancing.

Step 4: Maintain proper PPE for staff.
- Ensure adequate PPE for all staff members.
- Mask and eye protection should be worn during patient encounters, and patients should be wearing masks.
- Consider measures to conserve PPE as needed (ie, decontamination and reusing of masks).

Step 5: Schedule all patients, including virtual consultations.
- Prioritize urgent cases.
- Consider transitioning nonurgent cases and follow-ups to telemedicine.

Step 6: Organize your staff.
- Limit the number of staff members per room to facilitate physical distancing.
- Screen staff daily.
- Staff members who are experiencing COVID-19 symptoms should refrain from reporting to work and be referred to employee health services.

Step 7: Screen patients.
- Unless a companion or caregiver is needed (eg, minors or elderly in need of assistance), patients should come to the appointment alone.
- As much as possible, patients should come on their allotted schedule to minimize patient traffic and time spent in the waiting areas.
- All patients should be screened for COVID-19 (temperature and symptom check) before entering the clinic.
- Treat all patients as potentially infectious even if they pass screening.

Step 8: Communicate with your patients.
- Update your patients regarding practice adjustments and the possibility of any future changes as the pandemic situation evolves.

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.

Data from American Academy of Dermatology. Running Dermatology Practices During COVID-19. 2020. Available at: https://assets.ctfassets.net/1ny4yoiyxq1a/1VQz8nAZqLCiLe7fGNIXrQ/1230fd02e0b8d908b84905e1f57765/Running_Practices_During_Covid-19_12.03.20.pdf. Accessed February 12, 2021.
- Diagnostic procedures for confirmatory purposes, especially when the differential diagnosis includes high-risk conditions (eg, melanoma, severe infection, mycosis fungoides, autoimmune blistering diseases).
- Patients with skin disease resulting in significant functional and/or emotional impairment who have no access to or cannot effectively use telemedicine.
- Patients with similar prognoses should be selected randomly as to who gets a particular appointment.

In addition, COVID-19 screening (temperature and symptom check) and wearing of masks became a routine, and in most cases even a prerequisite for a patient or staff member to be allowed entry into the clinic. It is recommended that staff members who are suspected to have COVID-19, either through positive screening or exposure to an infected individual, be sent home and follow the Centers for Disease Control and Prevention (CDC) guidelines for returning to work following a COVID-19 exposure (Fig. 1). Overall, these adjustments were made

**Fig. 1.** Summary of CDC return to work criteria for healthcare staff who have been exposed to COVID-19. Exposure through close contact is defined by the CDC as being within 6 ft of an infected individual for at least 15 minutes without PPE. A previously asymptomatic staff member who starts to develop symptoms during 10-day isolation or while waiting for COVID-19 test results (dotted arrow) should follow the algorithm for symptomatic health care workers. Per CDC, fully vaccinated individuals (ie, ≥2 weeks and <3 months from receiving requisite vaccine doses) or who have recovered from COVID-19 infection less than 3 months earlier do not have to quarantine after a meaningful COVID-19 exposure as long as they remain asymptomatic. Data from Centers for Disease Control and Prevention (CDC). Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance). 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html. Accessed February 27, 2021.
to facilitate physical distancing and curtail viral transmission.

**Procedural Dermatology**

Based on a global Web-based survey, only 25% of dermatologists performed procedures during the height of the pandemic. Of these, biopsies and Mohs micrographic surgeries (MMSs) were the most commonly performed, whereas cosmetic procedures became exceedingly rare, which comes as no surprise, because most interim guidelines in 2020 recommended deferring elective cosmetic and surgical procedures to reduce the risk of COVID-19 transmission and preserve PPE. The International League of Dermatologic Societies defines elective dermatologic procedures as those performed on skin lesions that pose no imminent danger to the patient if not surgically removed within 3 months; these include acne surgery, chemical peels, laser hair removal, and injectables (botulinum toxin and cosmetic filler

### Table 1

American Society of Dermatologic Surgery Association and American Society for Laser Medicine and Surgery guidelines for cosmetic dermatology practice during the coronavirus disease 2019 pandemic

| Recommendation                                                                 | Level of Evidence | Strength of Recommendation |
|--------------------------------------------------------------------------------|-------------------|---------------------------|
| Use of masks by patients, physicians and staff                                 | Moderate          | Strong                    |
| Physician and staff masking for procedures near the nose and mouth             | Moderate          | Strong                    |
| Handwashing                                                                    | Moderate          | Strong                    |
| COVID-19 vaccination                                                           | Moderate          | Strong                    |
| Eye protection                                                                 | Moderate          | Moderate                  |
| Use of air suction or HEPA filters                                            | Moderate          | Weak/Option               |
| Use of upper-room UVGI                                                         | Moderate          | Weak/Option               |
| During prolonged skin procedures, properly fitted N95 respirators are           | Low               | Weak/Option               |
| a more effective form of protection than masks                                |                   |                           |
| Room size can influence the risk of COVID-19 infection (ie, larger rooms are  | Low               | Weak/Option               |
| associated with lower risk)                                                    |                   |                           |
| Longer patient contact time increases the risk of contracting COVID-19        | Low               | Weak/Option               |
| Procedures involving the head and neck carry greater risk of COVID-19         | Low               | Weak/Option               |
| transmission compared with procedures below the clavicle                     |                   |                           |
| Forced air cooling increases the risk of COVID-19 transmission vs contact     | Very low          | Weak/Option               |
| cooling during laser procedures                                              |                   |                           |
| Skin and hair procedures carry low risk of COVID-19 transmission              | Very low          | None                      |
| No documented risk of contracting COVID-19 from blood during procedures       | Very low          | None                      |
| No evidence that ablative laser procedures or liposuction increase the risk   | Very low          | None                      |
| of COVID-19 infection                                                          |                   |                           |

Abbreviations: ASDSA, American Society of Dermatologic Surgery Association; ASLMS, American Society for Laser Medicine and Surgery; HEPA, high-efficiency particulate air; UVGI, ultraviolet-C germicidal irradiation.

Data from Narla S, Alam M, Ozog D, et al. American Society of Dermatologic Surgery Association (ASDSA) and American Society for Laser Medicine & Surgery (ASLMS) Guidance for Cosmetic Dermatology Practices During COVID-19. 2021. Available at: https://www.aslms.org/docs/default-source/for-professionals/resources/asdsa-and-aslms-final-cosmetic-reopening-guidance-june2020.pdf?sfvrsn=c879e53b_2. Accessed February 12, 2021.
injections). Conversely, lesions such as melanoma, atypical melanocytic lesions, or abscess drainage may necessitate prompt management with surgery or other procedures, which should be done during the pandemic under strict infection prevention and control measures (see Box 2).

With regard to MMS, a United Kingdom-based nationwide survey revealed that almost half of surgeons performing MMS completely ceased services during the height of the pandemic, whereas 36% and 15% had reduced and normal operations, respectively.16 To minimize patient visits, those who continued to perform MMS showed an increased preference toward the use of absorbable sutures for wound closure, as well as telecommunications (telephone/video) for follow-up visits compared with before COVID-19.16 On the other hand, post-Mohs reconstructions performed by other specialties were significantly decreased (74%) together with face-to-face consultations (91% decrease).16

In early 2021, the American Society for Dermatologic Surgery together with the American Society for Laser Medicine and Surgery, Inc, released guidelines for the safe practice of cosmetic dermatology during COVID-19 (Table 1).17 The document detailed and graded ancillary evidence on various infection prevention and control measures (eg, mask/respirator use, eye protection, and handwashing), as well as the risk of viral transmission associated with certain dermatologic procedures.17

### Box 3
**Recommendations for phototherapy during the coronavirus disease 2019 pandemic**

**General recommendations**
- All patients should be scheduled.
- Schedule appointments not more than every 30 min to limit the number of patients treated per day, and allow adequate time for disinfection in between patients.
- Have all patients screened for COVID-19 symptoms before entering the phototherapy unit. Patients with symptoms may be refused treatment and referred to the appropriate COVID-19 referral unit.
- Patients should ideally come alone for their phototherapy appointment. If a companion is necessary (ie, patient is a minor, an elderly who requires assistance, or disabled), only 1 is allowed.
- All patients should wear a face mask, except during total-body phototherapy treatment.
- All staff and patient companions (if any) should wear a face mask.
- All patients, patient companions, and staff must practice strict hand hygiene at all times. These should include, but are not limited to, the following instances: before entering the phototherapy unit, before and after treatment (for patients), before and after the patient encounter (for staff), after touching high-touch surfaces, before exiting the phototherapy unit.
- Maintain physical distancing at all times.

**Recommendations for phototherapy treatment**
- Provide all patients with individual goggles to be stored in individualized bags inside the phototherapy unit. Goggles should be disinfected according to manufacturer's instructions before storage.
- Provide a bag for storage of the patient's clothes upon disrobing. Discard the bag at the end of treatment.
- Avoid turning on the fan in the phototherapy unit. Treatments may be fractionated if needed to avoid excessive heat build-up inside the unit.
- Staff should disinfect all high-touch areas and surfaces after each patient.

*Data from* Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM. Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):287–88 and Laconico-Tumalad LL, Sabido PWM, Sison-de Jesus C. Philippine Dermatological Society Photodermatology Subspecialty Core Group Post-Quarantine Guidelines for Phototherapy Centers. 2020. Available at: https://pds.org.ph/pds_new/wp-content/uploads/2020/06/PDS-Photodermatology-Post-ECQ-Guidelines-for-Phototherapy-FINAL.pdf. Accessed January 29, 2021.
centers worldwide were closed during the height of the pandemic, whereas the few that remained open experienced a decline in patient census. In one of the biggest health systems in Israel, the number of patients coming in for phototherapy decreased by more than 50% since March 2020.18 This decrease was found to be primarily driven by patients declining treatment continuation because of fear of contracting the virus; the interruption in care posed the risk of a skin disease flare.18 Photomunosuppression may also be of particular concern amid the pandemic, because it is one of the mechanisms by which phototherapy controls skin disease. However, based on clinical experience with human immunodeficiency virus–positive patients, phototherapy is a safe and reasonable option during this time.19

The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in phototherapy units is currently unknown.20 Although safety protocols observed in other hospital units are largely applicable, there are certain elements unique to phototherapy that require special attention. First, phototherapy involves having a patient come to the clinic multiple times a week, which potentially increases exposure to both the patient and staff. Second, localized treatments (ie, excimer laser or light) entail close contact between the patient and the staff for a prolonged period, and treatment of the face and periorificial areas where patients need to be unmasked puts the staff at even higher risk. Third, full-body treatments, although generally preferred during the pandemic, are typically administered in enclosed booths where patients stand in close proximity to phototherapy equipment surfaces made of plastic or steel.21 This proximity can potentially facilitate viral transmission because SARS-CoV-2 has been found to survive for up to 9 days on these surfaces,21 even though evidence of COVID-19 transmission through inanimate objects is limited. In addition, phototherapy booths normally have fans that are turned on during treatment to prevent overheating, which is potentially aerosolizing and could facilitate viral spread.22

Therefore, the decision to resume phototherapy should be made based on the weight of its perceived benefit versus the potential risks to both patient and staff. Most guidelines recommend prioritizing patients with severe skin disease, those who are more likely to respond to phototherapy, and in cases wherein other options besides phototherapy are limited or unavailable.20 Home phototherapy is also a reasonable option and may even be preferable during this time; however, it may not be feasible for all patients.

If in-office phototherapy is deemed necessary, efforts must be taken to conduct operations as safely as possible. Box 3 lists expert recommendations for operating phototherapy clinics during the COVID-19 pandemic.22,23

**SUMMARY**

|                      | Before COVID                                      | New Normal                                       |
|----------------------|---------------------------------------------------|--------------------------------------------------|
| **Dermatology**      | • Appointments for face-to-face consultation for  | • Increased utilization of teledermicine         |
| consultation         | outnumbered telemedicine visits                   | • Limited in-person appointments                 |
|                      | • Clinics follow normal office hours              | • Decreased clinic opening days and/or hours     |
|                      | • Patients can schedule in-person appointments   | • Prioritization of urgent and essential cases   |
|                      | regardless of the reason for consult             | for face-to-face visit                           |
|                      | • Screening, physical distancing, and wearing of face masks are generally not required |
|                      | • Appointments have short intervals and double bookings are acceptable |
|                      | • Patients are allowed to bring companions        | • Screening of patients for COVID-19 before clinic entry |
| **Dermatology**      | • Elective procedures are acceptable              | • Physical distancing                            |
| procedures           | • Postoperative patients have sutures removed    | • Wearing of face masks                          |
|                      | in-office                                         | • Increased time interval between appointments for disinfection |
|                      | • In-person postoperative visits are the norm     | • Patients are advised to come alone whenever possible |
| **Phototherapy**     | • Patients share a common set of goggles         | • Elective procedures are deferred to reduce viral transmission risk |
|                      | • Fans are turned on during treatment to avoid overheating |
|                      | • Multiple patients can be treated at once (ie, one patient in UV-B and one in UV-A) |
|                      | • Patients are given individual goggles          | • Use of absorbable sutures to eliminate additional visit for removal |
|                      | • Turning on of the fan is avoided to minimize potential aerosolization |
|                      | • Only one patient at a time is                   | • Virtual postoperative visits are more frequent |
|                      |                                                   |                                                  |

(continued on next page)
Future Perspectives

As of February 2021, a total of 72.8 million doses of COVID-19 vaccine have been administered in the United States, most which were first given to health care workers (HCWs).24 In Israel, which was the first country to vaccinate most of their population, fully vaccinated HCWs (2 doses of the Pfizer BioNT vaccine) comprised only 2% of those who contracted COVID-19; this compared favorably to partially vaccinated (1 dose received) and unvaccinated HCWs who comprised 46% and 52% of infections, respectively.25 Hence, with HCWs almost universally vaccinated, it is reasonable to expect that some easing of restrictions may take place. Per CDC guidance as of March 2021, individuals who are at least 2 weeks and less than 3 months from receiving the requisite doses of vaccine, or who have recovered from COVID-19 infection less than 3 months earlier, do not have to quarantine after a meaningful COVID-19 exposure as long as they remain asymptomatic.26,27 However, given its unpredictable nature, COVID-19 resurgence is a possibility and may warrant reinstatement of administrative and engineering mandates. The points summarized herein represent expert recommendation at the height of the pandemic.

- The appropriateness of teledermatology must be assessed on a case to case basis. Many patients and dermatologists feel comfortable using teledermatology to address common dermatoses; however, lesions which require closer examination (i.e. suspected malignancy) may warrant a face-to-face visit.

- Triaging of patients for scheduling in-person visits may be necessary. COVID-19 screening, wearing of masks, and physical distancing should still be practiced.

- Elective procedures should be deferred in order to reduce the risk of COVID-19 transmission and preserve personal protective equipment, while necessary procedures should be done under strict infection control and prevention measures.

- Many patients are reluctant to resume phototherapy for fear of contracting COVID-19. Home phototherapy, if feasible, is a reasonable option. Otherwise, in-office therapy should be resumed based on the perceived benefit versus potential risks, and should be conducted with safety protocols in place.

- Despite health care workers almost universally vaccinated, COVID-19 resurgence is still a possibility. Experts recommend that fully-vaccinated individuals continue to wear masks and practice physical distancing until more information becomes available.

- As the pandemic winds down, many of these recommendations/precautions can be safely relaxed.

DISCLOSURES

Dr Torres has no relevant disclosures. Dr Ozog is an investigator for Biofrontera. Dr Hruza has no financial disclosures. He is Chair of the American Academy of Dermatology COVID-19 Ad-Hoc Task Force.

REFERENCES

1. Field MJ. Telemedicine: a guide to assessing telecommunications in health care. Washington, DC: National Academies Press (US); 1996.
2. Romero G, Garrido JA, Garcia-Arpa M. [Telemedicine and teledermatology (I): concepts and applications]. Actas Dermosifiliogr 2008;99(7):506–22.
3. Su MY, Smith GP, Das S. Trends in teledermatology use during clinic reopening after COVID-19 closures. J Am Acad Dermatol 2021;84(4):213–4.
4. Landow SM, Mateus A, Korgavkar K, et al. Teledermatology: key factors associated with reducing face-to-face dermatology visits. J Am Acad Dermatol 2014;71(3):570–6.

5. Gupta R, Ibraheim MK, Doan HQ. Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray. J Am Acad Dermatol 2020;83(1):168–9.

6. Ng JN, Cembrano KAG, Wanitphakdeedecha R, et al. The aftermath of COVID-19 in dermatology practice: What’s next? J Cosmet Dermatol 2020;19(8):1826–7.

7. McKoy K, Antoniotti NM, Armstrong A, et al. Practice guidelines for teledermatology. Telemed J E Health 2016;22(12):981–90.

8. Litchman GH, Marson JW, Rigel DS. The continuing impact of COVID-19 on dermatology practice: Office workflow, economics, and future implications. J Am Acad Dermatol 2021;84(2):576–9.

9. Bhargava S, McKeever C, Kroumpouzos G. Impact of covid-19 pandemic on dermatology practices: results of a web-based, global survey. Int J Womens Dermatol 2020;17(2):217–23.

10. Nordal EJ, Moseng D, Kvammen B, et al. A comparative study of teleconsultations versus face-to-face consultations. J Telemed Telecare 2001;7(5):257–65.

11. American Academy of Dermatology. Running Dermatology Practices During COVID-19. 2020. Available at: https://assets.ctfassets.net/1ny4yoiyrqia/1VQd8nAZqLCiLe7fGNIXrQ/230fd02e0b8d908b84905e57765f1571/Running_Practices_During_Covid-19_12.03.2021.pdf. Accessed February 12, 2021.

12. Gerami P, Liszewski W. Risk assessment of outpatient dermatology practice in the setting of the COVID-19 pandemic. J Am Acad Dermatol 2020;83(5):1538–9.

13. Stoff BK, Blaickow TW, Swerlick RA, et al. Guiding principles for prioritization of limited in-person dermatology appointments during the COVID-19 pandemic. J Am Acad Dermatol 2020;83(4):1228–30.

14. Centers for Disease Control and Prevention (CDC). Return to Work Criteria for Healthcare Personnel with SARS-CoV-2 Infection (Interim Guidance). 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhealthcare-facilities%2Fhcp-return-work.html. Accessed February 27, 2021.

15. International League of Dermatological Societies. Guidance on the practice of dermatosurgery and cosmetic procedures during the COVID-19 (SARS-CoV-2, Coronavirus) pandemic (updated June 2020). 2020. Available at: https://ilds.org/wp-content/uploads/2020/06/ILDS-Guidance-on-the-practice-of-dermatosurgery-and-cosmetic-procedures-COVID-19-Update-June-2020.pdf. Accessed February 12, 2021.

16. Nicholson P, Ali FR, Mallipeddi R. Impact of COVID-19 on Mohs micrographic surgery: UK-wide survey and recommendations for practice. Clin Exp Dermatol 2020;45(7):901–2.

17. Narla S, Alam M, Ozog D, et al. American Society of Dermatologic Surgery Association (ASDSA) and American Society for Laser Medicine & Surgery (ASLMS) Guidance for Cosmetic Dermatology Practices During COVID-19. 2021. Available at: https://www.aslms.org/docs/default-source/for-professionals/resources/asdsa-and-aslms-final-cosmetic-reopening-guidance-june2020.pdf?sfvrsn=cc879e53b_2. Accessed February 12, 2021.

18. Fisher S, Ziv M. COVID-19 effect on phototherapy treatment utilization in dermatology. J Dermatol Treat 2020;1–3.

19. Torres AE, Lyons AB, Hamzavi IH, et al. Role of phototherapy in the era of biologics. J Am Acad Dermatol 2021;84(2):479–85.

20. Aguiler P, Gilaberte Y, Perez-Ferriols A, et al. Management of phototherapy units during the COVID-19 pandemic: Recommendations of the AEDV’s Spanish Photobiology Group. Actas Dermosifiliogr 2021;112(1):73–5.

21. Lim HW, Feldman SR, Van Voorhees AS, et al. Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol 2020;83(1):287–8.

22. Laconico-Tumalad LL, Sabido PWM, Sison-de Jesus C. Philippine Dermatological Society Photodermatology Subspecialty Core Group Post-Quarantine Guidelines for Phototherapy Centers. 2020. Available at: https://pds.org.ph/pds_new/wp-content/uploads/2020/06/PDS-Photodermatology-Post-ECQ-Guidelines-for-Phototherapy-FINAL.pdf. Accessed January 29, 2021.

23. Centers for Disease Control and Prevention (CDC). COVID-19 Vaccinations in the United States. 2021. Available at: https://covid.cdc.gov/covid-data-tracker/#vaccinations. Accessed February 27, 2021.

24. Amit S, Regev-Yochay G, Afek A, et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 2021;397(10277):875–7.
27. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. 2021. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed February 28, 2021.

28. Centers for Disease Control and Prevention (CDC). Frequently Asked Questions about COVID-19 Vaccination. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html. Accessed February 27, 2021.